Research

Mixed

Canagliflozin treatment in patients with type 2 diabetes mellitus reduces cardiovascular risk factors by inducing mild osmotic diuresis, natriuresis, and weight loss, leading to significant reductions in blood pressure and body weight.

For patients with Type 2 Diabetes and high cardiovascular risk, canagliflozin (100-300 mg daily) offers benefits beyond blood sugar control, specifically lowering blood pressure and body weight through fluid loss and caloric excretion. This multifactorial risk reduction is recommended by guidelines for patients with existing cardiovascular disease, provided their kidney function (eGFR) is above 45 mL/min/1.73 m2.

GoodSupportsHIGH confidence
This review article describes the effects of canagliflozin on cardiovascular risk factors based on results from its clinical development programme. ... Canagliflozin treatment has been shown to provide glycaemic improvements as well as reductions in blood pressure and body weight across a broad range of patients with T2DM, including those with elevated cardiovascular risk.
Matthew J. Budoff et al. · International Journal of Clinical Practice · 2017

Why this rating

Based on a review of multiple Phase 3 clinical trials and pooled data, though it is a review article rather than a single primary RCT.

Source

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus

Matthew J. Budoff et al. · International Journal of Clinical Practice · 2017

DOI 10.1111/ijcp.12948

narrative_review · n=10000Cited 27×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →